Viracta Therapeutics, Inc.
VIRX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $120 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $492 | $210 | $178 | $32 |
| Gross Profit | -$492 | -$210 | -$178 | $88 |
| % Margin | – | – | – | 73.3% |
| R&D Expenses | $33,369 | $26,262 | $23,861 | $13,467 |
| G&A Expenses | $17,324 | $24,327 | $15,437 | $5,348 |
| SG&A Expenses | $17,324 | $24,327 | $15,437 | $5,348 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$13,500 | -$34 |
| Operating Expenses | $50,693 | $50,589 | $25,798 | $18,815 |
| Operating Income | -$50,693 | -$50,589 | $62,502 | -$18,815 |
| % Margin | – | – | – | -15,679.2% |
| Other Income/Exp. Net | -$365 | $1,392 | -$75,464 | -$202 |
| Pre-Tax Income | -$51,058 | -$49,197 | -$114,762 | -$19,017 |
| Tax Expense | $0 | $577 | $88,300 | $182 |
| Net Income | -$51,058 | -$49,774 | -$203,062 | -$19,199 |
| % Margin | – | – | – | -15,999.2% |
| EPS | -1.32 | -1.32 | -6.37 | -0.52 |
| % Growth | 0% | 79.3% | -1,125% | – |
| EPS Diluted | -1.32 | -1.32 | -6.37 | -0.52 |
| Weighted Avg Shares Out | 38,624 | 37,791 | 31,870 | 37,108 |
| Weighted Avg Shares Out Dil | 38,624 | 37,791 | 31,870 | 37,108 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,345 | $1,171 | $38 | $48 |
| Interest Expense | $3,704 | $577 | $491 | $216 |
| Depreciation & Amortization | $492 | $210 | $178 | $32 |
| EBITDA | -$46,862 | -$48,410 | -$114,093 | -$18,769 |
| % Margin | – | – | – | -15,640.8% |